NOD2- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn’s disease patients

Table 4 Characteristics of the patients -nucleotide-binding oligomerization domain 2 status, classification and activity of the disease, C-reactive protein and vitamin D levels, and medication at the time of the study

No.	Sex	Age	NOD2	Montreal classification	CDAI	CRP (mg/L)	Vitamin D (nmol/L)	Prednisolon (> 10 mg/d)	Azathio-prine	Anti-TNF-α
1	M	24	WT1	A2 L3 L4 B1	121	2.58	104.0	Yes	No	Yes
2	M	28	WT1	A2 L3 B3p	46	< 1.0	62.9	No	No	Yes
3	M	64	WT1	A3 L3 B2p	111	4.58	27.0	Yes	No	Yes
4	F	60	WT	A2 L3 B2	100	2.27	72.5	No	No	Yes
5	F	62	WT	A3 L3 B3p	82	< 1.0	58.2	Yes	Yes	Yes
6	M	46	WT	A2 L3 L4 B2p	110	4.97	32.9	No	No	Yes
7	M	38	HO	A2 L3 B3p	92	13.30	40.2	No	Yes	No
8	M	64	HO	A3 L3 B1	34	< 1.0	53.0	No	No	Yes
9	F	48	HO2	A2 L3 B2	54	< 1.0	67.6	No	No	Yes
10	M	54	HO	A2 L3 B2p	103	1.63	51.9	No	Yes	No
11	M	26	HO	A1 L3 B2p	120	7.86	31.0	No	Yes	Yes
12	M	27	HT	A2 L3 B1	106	1.41	47.2	No	No	Yes
13	M	37	HT	A2 L3 B2p	166	4.56	37.9	No	Yes	No
14	F	48	HT	A2 L1 B3p	115	1.01	55.2	No	Yes	Yes
15	M	57	HT	A1 L3 B2p	132	12.30	52.3	No	No	Yes
16	M	47	HT	A2 L3 B3	60	2.62	92.0	No	Yes	No

¹Patients who were also included into microarray analysis;

²SNP8 mutation. All other HO/HT mutations refer to SNP13. NOD2: Nucleotide-binding oligomerization domain 2; CDAI: Crohn’s disease activity index; CRP: C-reactive protein; TNF : Tumor necrosis factor; WT: Wild-type; HO: Homozygous mutation; HT: Heterozygous mutation.